Capricorn Investment Group Takes 20% Stake in Norselab's European Impact Investment Platform
4.1.2022 21:54:00 EET | Business Wire | Press release
Capricorn Investment Group makes their first move into the Nordic venture space with their investment in Norselab, an Oslo-based European impact investment manager for private capital.
“With their thoughtful approach to innovative impact investments, Norselab stands out as an ideal partner to expand our presence into the Nordics and Europe. We are thrilled to help scale their impact investment platform,” says Michaela Edwards, Partner at Capricorn Investment Group.
Edwards is the partner in charge of the investment into Norselab. The deal, offering Capricorn’s Sustainable Investment Fund a 20% stake in Norselab, relied heavily on their belief in the team and the structure that they have built.
“The team behind Norselab has an outstanding track record in building and scaling tech companies, in addition to a clear ambition to build a larger ecosystem of funds. These were key factors weighing in on our investment decision,” adds Edwards.
Both firms share the belief that impact investments will offer the best opportunities over the coming decades. Through investment into companies that target industries in need of transformation, Norselab aims to ignite disruption, and to create potential for solid returns and massive impact.
Unexplored opportunities in the Nordics
Capricorn’s investment in Norselab marks its first, strategic move into the Nordics. According to Edwards, the Nordics are still unexplored territory from a global perspective, and offer plentiful opportunities for both impact and high returns. She highlights that Norway, with its ongoing green shift and hunger for innovation, offers a great location from which Norselab can expand to Europe.
Building system value
Norselab launched its first impact-focused venture fund, Meaningful Equity I, in 2020. On the back of a solid tailwind in terms of market trends and deal flow, the impact investor is expanding its platform with several new funds. This means a significant upscaling of the organization where creating system value through knowledge sharing is the key to accelerate growth and value creation across the ecosystem.
“Our partnership with Capricorn Investment Group will connect us with their globally leading impact investment ecosystem. Being part of their impact funds also means that our portfolio companies will gain greater access to international resources, co-investors and talents,” says Yngve Tvedt, Norselab Founder and Chief Investment Officer.
Uncompromising on impact
Tvedt adds that Capricorn’s solid impact profile was decisive for Norselab’s decision to bring on board a larger capital partner.
“Impact is at the heart of our investment philosophy, and core to the products and services of the companies we invest in. We want to build Norselab into a leading European impact investment platform, and believe Capricorn is a match made in heaven for scaling Norselab while staying true to our fundamental DNA,” says Tvedt.
With the Sustainable Investment Fund, Capricorn Investment Group aims to back purpose-built investment managers with an authentic vision around impact.
“We’re not in business to create incremental change, we are aiming to drive systemic change,” comments Edwards.
A fit-for-scale platform
Norselab’s CEO, Erik Syvertsen, explains how they created an international fund platform for venture investments with the building blocks that most market participants would recognize from larger institutional structures.
“As we established our first fund, we knew that a robust infrastructure with scalability would be essential if we were to have international ambitions both in terms of deal flow and the ability to attract capital. Capricorn recognized the value in the ecosystem we are aiming to build in and around Norselab. It’s a privilege for us to work with a capital partner that is aligned with our values and ambitions across the board,” says Syvertsen.
Norwegian capital partners joining the party
Two significant Norwegian capital partners are also part of the deal. Long-term Norselab investor Ness, Risan & Partners, invests in the impact investment platform to offer Norselab’s attractive impact products to their large Nordic customer base. Joakim Lehmkuhl is also among the new capital partners. His connection to international investor groups will give the Norselab team solid traction to scale its platform out of Norway.
About Capricorn
Capricorn is one of the largest mission-aligned firms in the world, and has since its inception in 2000 grown to manage more than $10 billion in multi-asset classes for foundations and institutional investors, through their range of impact-focused fund products. Their Sustainable Investors Fund (SIF) is a private equity partnership whose investment objective is to create significant value through ownership and early stage investment in public and private asset managers who incorporate sustainability as a key driver of investment returns.
The firm has offices in New York City and Palo Alto, and was born from a belief that sustainable investment practices can enhance risk-adjusted returns. Underlying this investment approach is a deep desire to demonstrate the huge investment potential that resides in breakthrough commercial solutions to the world’s most pressing problems.
About Norselab
Norselab is a leading impact investment platform based out of Oslo, Norway. With an uncompromising focus on net positive impact, Norselab invests in fast-growing, meaningful companies that ignite radical changes in traditional industries.
Norselab established their internationally regulated fund structure in 2020, and closed their first venture fund, Norselab Meaningful Equity I, in 2021. Norselab is currently scaling up its activities, and plans to launch several new funds in 2022, all with impact at their core.
About Ness, Risan & Partners
Ness, Risan & Partners AS (NRP) is an independent and privately-owned investment firm. Its clients include family offices, private investors, investment companies, foundations, trusts and institutional investors. NRP offers direct investment and fund solutions within the real estate, shipping and offshore sectors. The company was founded in 2000 by Christian Ness and Ragnvald Risan, and has more than 70 employees and an AUM of more than $ 1Billion.
Interviews on request.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005857/en/
Contact information
Media contact:
Maria de Perlinghi
Partner, Impact & Communications at Norselab
+47 92221959
maria@norselab.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
